Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed recombinant fusion protein compositions that inhibit pathological angiogenesis by targeting VEGF165-KDR interactions to treat cancers and related diseases.

Researchers at the University of California, Davis have developed methods that combine immunotherapeutic agents with dual inhibitors to enhance cancer treatment efficacy and prolong patient survival.

Researchers at the University of California, Davis have developed a peptide nucleic acid-based system enabling precise and customizable delivery of antigens, adjuvants, and targeting molecules for improved cancer immunotherapy.

Researchers at the University of California, Davis have developed novel serotonin receptor modulators designed as mixed 5-HT2A/2C partial agonists that demonstrate promising disease-modifying potential for Parkinson’s Disease with improved safety and efficacy.

Brief description not available

Researchers at the University of California, Davis have developed a system of reusable, sterilizable 3D-printed surgical tools that enables safe, precise intraoperative deployment of Neuropixels probes within standard neurosurgical workflows.

Antibiotic resistance is a major issue in infectious disease treatment and prevention. In bacteria, the type III secretion system (T3SS) secretes effector proteins in the host cell, allowing the pathogen to infect. The T3SS is largely found on pathogens and not beneficial bacteria, so targeting the T3SS might have an advantage over using classic antibiotics, which disturb the beneficial human microbiome.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a technology that introduces vaccines that express macrophage-suppressing molecules to significantly enhance inflammatory T-cell functions for improved immune responses.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed isolated peptides that selectively bind M1 and M2 macrophages to enable precise diagnosis and targeted treatment of macrophage-associated diseases, including cancer.

Researchers at the University of California, Davis have developed an advancement in the field of healthcare technology, specifically in the development and application of silyl lipids for RNA vaccines.